Autologous T cells engineered to secrete IL-12 and to target MUC16ecto
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous T cells engineered to secrete IL-12 and to target MUC16ecto, covering 2025-07-31 to 2025-07-31. Get the full timeline:
Most recent: Clinical Trial Update: Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors [Phase 1]